Interventional Oncology Devices – Market Insights – United States

The US market for interventional oncology devices will grow through 2032. This will be driven largely by the increasing shift toward higher-priced technologies, such as radioembolization, and expanding populations that are treatable with ablation.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in the US from 2019 through 2032.

The COVID-19 pandemic had short term consequences on the interventional oncology device market.

To what extent did COVID-19 affect the different procedure types in the interventional oncology device market?

How has recovery progressed in this space?

The adoption rates of different ablation modalities have shifted in recent years.

How will growth vary across different ablation device categories?

How strongly are cryoablation and IRE ablation being adopted?

What are the key ongoing clinical trials related to ablation, and what implications might they have on the interventional oncology device market?

Newer embolization technologies are seeing increasing adoption.

What is the adoption outlook for different embolization devices, and what factors will affect the uptake of these technologies over the forecast period?

What impact will clinical guidance have on the adoption of newer technologies in the embolization device market?

How will the adoption of radioembolization spheres be affected by recent clinical trials?

Table of contents